ADVOCACY FOR NEUROACANTHOCYTOSIS PATIENTS
Through personal contact and a news letter the Advocacy supports patients with neuroacanthocytosis and their families around the world. We are also an important initiator and financial supporter of education including research into the clinical and basic science of these neurodegenerative diseases.
Financial health, per its FY2025 accounts
The accounts state that the charity ended the year with total funds of £234,214, an increase from the previous year's £203,425. The trustees report that the charity has very limited expenses and commits its full resources to educational and research work, supported by one full-time paid staff member and volunteers.
What the accounts disclose
“The Advocacy's policy is to commit its full resources to its educational and research work each year.” — page 4
Trustees
- GINGER IRVINEchair
- Dr Peter George Mills
- Mary Elizabeth Leigh-Wood
- Nicola Keat
- Professor Dr Adrian Danek
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/08/2025 | £71k | £47k |
| 31/08/2024 | £50k | £52k |
| 31/08/2023 | £9k | £34k |
| 31/08/2022 | £90k | £17k |
| 31/08/2021 | £15k | £89k |
Common questions
Is ADVOCACY FOR NEUROACANTHOCYTOSIS PATIENTS financially healthy?
Per its FY2025 accounts: The accounts state that the charity ended the year with total funds of £234,214, an increase from the previous year's £203,425. The trustees report that the charity has very limited expenses and commits its full resources to educational and research work, supported by one full-time paid staff member and volunteers. Its FY2025 accounts were independently examined.